The FDA issued a warning letter to Empower Pharmacy on September 18, 2026, with a decision that closes one of the most widely used arguments for keeping compounded semaglutide and tirzepatide flowing after both drugs came off the FDA drug shortage list. The agency ruled that adding vitamin B12 or niacinamide to a compounded GLP-1 formulation does not make the product meaningfully different (legally, "not essentially a copy") of the brand-name drug it was designed to replace.
By Alexandru Vieru | Independently researched | Published October 2026. Regulatory information reflects FDA public records and published legal analysis through September 2026.
Bottom line: If your current compounded GLP-1 includes added B12 or niacinamide as part of the formulation, ask your clinic whether their pharmacy still ships that exact combination. Plain compounded semaglutide from a licensed 503A pharmacy for an individual prescription, without added ingredients used solely to argue distinctness, remains legal under a different framework and was not targeted by this letter.
Why the B12 Combination Existed in the First Place
When the FDA removed semaglutide from its drug shortage list in February 2025 (tirzepatide in October 2024), it also removed the clearest legal basis for large-scale compounding. The shortage designation had given 503A and 503B compounders an explicit statutory foothold to produce the same active ingredient as Ozempic, Wegovy, Zepbound, and Mounjaro. Once the shortage ended, the legal argument had to shift.
The most common workaround: formulate the compound to include a second ingredient (most often vitamin B12 as cyanocobalamin, or niacinamide) that isn't present in the brand-name drug. The argument goes that the product is now clinically distinct from the FDA-approved formulation, and therefore not "essentially a copy" under Section 503A of the Food, Drug, and Cosmetic Act.
Dozens of compounding pharmacies and hundreds of telehealth clinics adopted this approach. For many patients, the product they were receiving had quietly shifted from plain compounded semaglutide to a semaglutide-plus-B12 formulation with little disclosure about why.
FDA's September 18 warning letter to Empower Pharmacy addresses this directly.
What FDA Actually Said
The agency's ruling applies the "essentially a copy" standard under FDCA Section 503A. Under that provision, a 503A pharmacy may compound a drug that is essentially a copy of a commercially available drug only for individual patients who have a specific documented clinical need that the commercial drug cannot meet, such as an allergy to an inactive ingredient. Simply adding B12 or niacinamide, FDA stated in the September 18 letter, does not establish the clinical differentiation required. The agency found no demonstrated patient-specific therapeutic rationale for the added ingredient that could not be addressed by prescribing B12 separately.
The products FDA targeted: compounded tirzepatide with niacinamide and compounded semaglutide with cyanocobalamin (B12). Both were sold commercially at scale, not compounded individually per patient need.
This is a different kind of enforcement than previous FDA actions against telehealth clinics. Earlier warning letters, including waves sent in September 2025 and February 2026, targeted marketing claims on clinic websites for implying equivalence between compounded and FDA-approved products. This letter targets the underlying compounding practice itself at the pharmacy level.
The Difference Between 503A and 503B
The September 18 letter went to Empower Pharmacy. Understanding how that fits into the larger picture requires knowing the two federal frameworks for compounding.
| Framework | Who it covers | Shortage required? | Fall 2026 status |
|---|---|---|---|
| 503A pharmacy | Patient-specific prescriptions only | No, but may not compound "essentially a copy" unless patient-specific clinical need | ⚠️ Plain compound legal; B12/niacinamide combos now challenged |
| 503B outsourcing facility | Bulk production without individual Rx | Yes. Both GLP-1 shortages are resolved | ❌ No valid shortage basis for GLP-1 since early 2025 |
Empower Pharmacy operates at the scale of both a 503A and 503B facility. The September 18 letter addresses conduct under the 503A framework. Specifically, that the added-ingredient workaround doesn't satisfy the individual-patient-need requirement.
Who Is Empower Pharmacy
Empower Pharmacy (Empower Clinic Services, LLC) is headquartered in Houston, Texas, and is one of the largest compounding pharmacies in the United States. It has been a major supplier for telehealth GLP-1 programs.
This is not Empower's first FDA warning letter. The agency sent an earlier letter in April 2025 related to sterile manufacturing conditions at its Houston facility, and a letter in 2021 covering the same category. Neither of those letters named the GLP-1 product line specifically. The September 2026 letter is the first to target the formulation strategy directly.
We track Empower's regulatory record because some telehealth clinics publicly name their pharmacy fulfillment partners. When a clinic discloses which compounding pharmacy fulfills its GLP-1 prescriptions, past FDA enforcement against that pharmacy is relevant information for a patient deciding whether to use that clinic.
What This Means for Your Compounded Semaglutide
If your formulation includes B12 or niacinamide:
Check with your clinic. The September 18 letter creates regulatory pressure on pharmacies shipping this formulation at scale. Some may have already reformulated; others may have stopped shipping the combination. The clinic's response to you is informative. A clinic that has thought through its regulatory exposure will know whether its pharmacy partner was affected and what it changed.
If your formulation is plain compounded semaglutide:
Plain compounded semaglutide from a licensed 503A pharmacy, prepared for an individual prescription without added ingredients for distinctness arguments, was not the target of the September 18 letter. The 503A framework still allows patient-specific compounding for documented clinical need: for example, a patient who needs a specific concentration not available commercially, or who has a documented allergy to an inactive ingredient in the brand-name product.
If you are on brand-name Wegovy, Ozempic, Zepbound, or Mounjaro:
This regulatory development does not affect you. Your product is FDA-approved and not involved.
Table: What's Legal, What's in Question
| Situation | Legal status (Oct 2026) |
|---|---|
| Plain compounded semaglutide from a 503A pharmacy, patient-specific Rx, no added distinctness ingredient | ✅ Legal under 503A patient-specific framework |
| Compounded semaglutide + B12 (cyanocobalamin), commercial scale, no documented patient-specific need | ⚠️ Challenged: September 18 FDA warning to Empower; pharmacy-level enforcement risk |
| Compounded tirzepatide + niacinamide, commercial scale | ⚠️ Challenged: same warning letter |
| Bulk compounded GLP-1 from a 503B outsourcing facility (no active shortage) | ❌ No valid legal basis since shortages resolved |
| Brand-name Wegovy / Ozempic / Zepbound / Mounjaro | ✅ FDA-approved, not affected |
What to Ask Your Clinic
If you are currently using a compounded GLP-1 and want to assess your exposure:
- Does your prescription include B12, cyanocobalamin, niacinamide, or any other added ingredient? If yes, ask your clinic what clinical rationale is on file for that addition in your chart.
- Which pharmacy compounds and ships your medication? A clinic that declines to name its pharmacy is a transparency signal worth noting.
- Has your pharmacy changed its GLP-1 formulation recently? Pharmacies that were aware of the FDA's enforcement direction may have shifted formulations before the September 18 letter was publicly filed.
- What happens if your pharmacy stops shipping this formulation? Ask whether the clinic works with a backup pharmacy and what transition looks like.
Context: How FDA Enforcement Has Escalated
The September 18 Empower letter fits a pattern of escalating FDA enforcement targeting the compounded GLP-1 space:
- September 2025: FDA sent letters to roughly 80 telehealth clinics for marketing claims implying that compounded GLP-1s are equivalent to FDA-approved drugs.
- February 2026: FDA sent a second wave of about 30 letters focused on specific website claim language and branding that implied the clinic itself was the manufacturer.
- September 2026: FDA now targets the pharmacy level, specifically the formulation strategy used to claim legal distinctness.
Each wave has moved closer to the actual compounding operation. The September 18 letter is the first to address the compound itself, not just how it was marketed or labeled.
Clinics That Disclose Their Sourcing
In our ranking, we score each clinic on clinical oversight, pricing transparency, and medication options. Transparency includes whether a clinic discloses which pharmacy compounds its medications and what formulation it ships. Clinics that are upfront about their supply chain are better positioned for the kind of question you need to ask now.
Our full ranking shows clinical oversight scores for every reviewed clinic. If regulatory transparency matters to your decision, our review methodology on the editorial policy page explains how we score it.
Top pick for regulatory resilience: Visit Wellorithm →. The highest-rated clinic in our rankings at 7.9/10, offering both compounded semaglutide and brand-name GLP-1 options on one platform.
⚠️ Regulatory disclaimer: Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are prepared by licensed pharmacies under state and federal compounding law. They have not undergone FDA's drug approval process for safety, efficacy, or manufacturing quality. This article describes regulatory actions and legal frameworks as reported in publicly available FDA records and legal analysis. It is not legal or medical advice.
Frequently Asked Questions
Is compounded semaglutide still legal in 2026?
Plain compounded semaglutide from a licensed 503A pharmacy, made for an individual patient prescription, remains legal in all 50 states. The September 18 warning letter specifically targeted modified formulations (semaglutide + B12 or tirzepatide + niacinamide) at commercial scale. Plain compound, properly prescribed, was not the target. For background on the 503A framework, see our compounded semaglutide legality guide.
Does FDA's warning to Empower mean Empower will stop shipping GLP-1?
Warning letters are enforcement notices, not shutdown orders. Empower can respond with corrective actions. As of publication, no court order or consent decree has required Empower to stop operations. Patients using a clinic that sources from Empower should ask their clinic what, if anything, has changed in their pharmacy's formulation or shipping.
If my clinic already switched me from B12 compound to plain compound, do I need to worry?
A clinic that proactively reformulated before or after the September 18 letter demonstrates it was paying attention to FDA's direction. Plain compounded semaglutide for a patient-specific prescription, with a valid clinical rationale on file, was not targeted. Ask your clinic to confirm the current formulation and the documented reason it was prescribed to you.
Does this change which clinic I should choose?
Not necessarily. The September 18 letter is about formulation practice at the pharmacy level. A clinic's regulatory exposure depends on which pharmacy it uses and how that pharmacy has responded. Clinics with transparent supply chains and named pharmacy partners are easier to assess. Our best online GLP-1 clinics ranking includes transparency scores as part of the overall rating.
For ongoing regulatory updates, see our compounded semaglutide fall 2026 supply overview and semaglutide ban tracker. For pricing comparison across all ranked clinics, see our GLP-1 cost guide.
External source: FDA human drug compounding overview and FDA warning letters database.
